Robert Locklear: Prasugrel associated with increased major bleeding in high-risk patients with stable coronary artery disease

Monday, August 31, 2015

Prasugrel associated with increased major bleeding in high-risk patients with stable coronary artery disease

Prasugrel-based dual antiplatelet therapy is associated with increased major bleeding after stent implantation for high-risk patients with stable coronary artery disease, according to a secondary analysis of the BASKET-PROVE II trial. Major bleedings were more pronounced in elderly and low-weight patients and raise concerns about the safety of prescriptions in these patients.